REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer
To determine whether adding panitumumab, an antibody against the epidermal growth factor receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX), improves the duration of survival of patients with advanced stomach and oesophageal cancer.
Oesophago-gastric Cancer
DRUG: epirubicin, oxaliplatin, capecitabine (EOX)|DRUG: EOX + panitumumab
Overall survival, Study closed early due to lack of efficacy, Early termination
response rate, toxicity, quality of life and PFS, Study closed early due to lack of efficacy, Early termination
Multicentre phase III, open labelled, randomised controlled trial. Randomisation will be 1:1 Arm A EOX and Arm B EOX + panitumumab. There will be a pilot phase II study of which the first 200 patients will be randomised and the primary endpoint for interim analysis will be when these patients have completed 6 months follow-up